Drugs / mRNA-1273.351
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04785144 | Mar 2021 → Jul 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05289037 | Mar 2022 → Nov 2023 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT04405076 | May 2020 → Oct 2021 | Orthocoronavirinae infectious disease | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1273.351 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04785144 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1273.351 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine” NCT04785144 ↗ |
| Route | Intramuscular | “1 IM booster dose of 20 ug of mRNA 1273.351 on Day 1” NCT04405076 ↗ |